Motor Neuron Disease Motor Neuron Disease

Total Page:16

File Type:pdf, Size:1020Kb

Motor Neuron Disease Motor Neuron Disease Motor Neuron Disease Motor Neuron Disease • Incidence: 2-4 per 100 000 • Onset: usually 50-70 years • Pathology: – Degenerative condition – anterior horn cells and upper motor neurons in spinal cord, resulting in mixed upper and lower motor neuron signs • Cause unknown – 10% familial (SOD-1 mutation) – ? Related to athleticism Presentation • Several variations in onset, but progress to the same endpoint • Motor nerves only affected • May be just UMN or just LMN at onset, but other features will appear over time • Main patterns: – Amyotrophic lateral sclerosis – Bulbar presentaion – Primary lateral sclerosis (UMN onset) – Progressive muscular atrophy (LMN onset) Questions Wasting Classification • Amyotrophic Lateral Sclerosis • Progressive Bulbar Palsy • Progressive Muscular Atrophy • Primary Lateral Sclerosis • Multifocal Motor Neuropathy • Spinal Muscular Atrophy • Kennedy’s Disease • Monomelic Amyotrophy • Brachial Amyotrophic Diplegia El Escorial Criteria for Diagnosis Tongue fasiculations Amyotrophic lateral sclerosis • ‘Typical’ presentation (60%+) • Usually one limb initially – Foot drop – Clumsy weak hand – May complain of cramps • Gradual progression over months • May be some wasting at presentation • Usually fasiculations (often more widespread) • Brisk reflexes, extensor plantars • No sensory signs; MAY occasionally be mild symptoms • Relentless progression, noticable over weeks/ months Bulbar MND • Approximately 30% of cases • Onset with dysarthria, dysphagia • Bulbar and pseudobulbar symptoms • On examination – Dysarthria – Tongue wasting, fasciculation – Brisk jaw jerk – May be other limb symptoms (but not always) • Progression more rapid than ALS presentation • Worse prognosis (approx 2 years) Other presentations • Primary lateral sclerosis (5%) – Pure UMN onset • Progressive muscular atrophy (5%) – Pure LMN onset – May be ‘flail limb’ appearance • Probably slightly better prognosis Progressive bulbar palsy Difficulty breathing Muscle weakness Motor neuron disease II Differential diagnosis • Diagnosis is clinical – EMG/ imaging may help • MND is fatal – exclude other, less severe/treatable conditions – Multilevel cervical/ lumbar degerative changes • May cause myelopathy + LMN features and fasciculation • Usually have sensory symptoms – Benign fasciculation syndrome – Bulbar – cerebrovascular disease, MND – Multifocal motor neuropathy – Hereditary spastic paraplegia – Kennedy’s disease (SMA) Investigations • Clinical diagnosis • Check CK – modest elevation • Investigations often aimed at excluding other causes – Often MRI cervical/lumbar spine – May image brain • NCS/ EMG show “chronic active denervation” in areas supplied by multiple nerve roots (note this pattern may be seen in one territory by radiculopathy) • Tongue/ Sternomastoid EMG sometimes performed Treatment • Riluzole – Glutamate antagonist – May extend left expectancy slightly (3-5 months on average) – Low side effect profile • Occ nausea, fatigue • Can disturb LFTs (needs monitoring at onset) – Expensive (?cost/ benefit) • Palliative – Nutrition • Soft diet • ‘Chin tuck’ – Hyoscine (excessive secretions/salivation) – Opiates/ benzodiazepines MND dementia • Proportion of patients develop frontotemporal dementia – Flat affect – Disinhibition – Language disturbance/ dysphasia – Impaired ‘executive function’ Cervical spondylomyelopathy vs Motor neuron disease • Flaccid weakness UL, shoulder girdle • Wasting of all small hand muscles • Inverted supinator • MyeloCT scan – spinal stenosis C4-C6 • EMG – denervation of UL muscles Motor Neuron Disease • Look for signs • Differential diagnosis • Counselling • Good luck.
Recommended publications
  • Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration with Motor Neuron Disease
    ORIGINAL CONTRIBUTION Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease Keith A. Josephs, MST, MD; Joseph E. Parisi, MD; David S. Knopman, MD; Bradley F. Boeve, MD; Ronald C. Petersen, MD, PhD; Dennis W. Dickson, MD Background: Frontotemporal lobar degeneration with evidence of motor neuron disease. Semiquantitative motor neuron disease (FTLD-MND) is a pathological analysis of motor and extramotor pathological findings entity characterized by motor neuron degeneration and revealed a spectrum of pathological changes underlying frontotemporal lobar degeneration. The ability to detect FTLD-MND. Hippocampal sclerosis, predominantly of the clinical signs of dementia and motor neuron disease the subiculum, was a significantly more frequent occur- in pathologically confirmed FTLD-MND has not been rence in the cases without clinical evidence of motor assessed. neuron disease (PϽ.01). In addition, neuronal loss, gliosis, and corticospinal tract degeneration were less Objectives: To determine if all cases of pathologically severe in the other 3 cases without clinical evidence of confirmed FTLD-MND have clinical evidence of fronto- motor neuron disease. temporal dementia and motor neuron disease, and to de- termine the possible reasons for misdiagnosis. Conclusions: Clinical diagnostic sensitivity for the el- ements of FTLD-MND is modest and may be affected by Method: Review of historical records and semiquantita- the fact that FTLD-MND represents a spectrum of patho- tive analysis of the motor and extramotor pathological find- logical findings, rather than a single homogeneous en- ings of all cases of pathologically confirmed FTLD-MND. tity. Detection of signs of clinical motor neuron disease is also difficult when motor neuron degeneration is mild Results: From a total of 17 cases of pathologically con- and in patients with hippocampal sclerosis.
    [Show full text]
  • Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia
    brain sciences Review Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia Timothy Fullam and Jeffrey Statland * Department of Neurology, University of Kansas Medical Center, Kansas, KS 66160, USA; [email protected] * Correspondence: [email protected] Abstract: Following the exclusion of potentially reversible causes, the differential for those patients presenting with a predominant upper motor neuron syndrome includes primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), or upper motor neuron dominant ALS (UMNdALS). Differentiation of these disorders in the early phases of disease remains challenging. While no single clinical or diagnostic tests is specific, there are several developing biomarkers and neuroimaging technologies which may help distinguish PLS from HSP and UMNdALS. Recent consensus diagnostic criteria and use of evolving technologies will allow more precise delineation of PLS from other upper motor neuron disorders and aid in the targeting of potentially disease-modifying therapeutics. Keywords: primary lateral sclerosis; amyotrophic lateral sclerosis; hereditary spastic paraplegia Citation: Fullam, T.; Statland, J. Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper 1. Introduction Motor Neuron Dominant Jean-Martin Charcot (1825–1893) and Wilhelm Erb (1840–1921) are credited with first Amyotrophic Lateral Sclerosis, and describing a distinct clinical syndrome of upper motor neuron (UMN) tract degeneration in Hereditary Spastic Paraplegia. Brain isolation with symptoms including spasticity, hyperreflexia, and mild weakness [1,2]. Many Sci. 2021, 11, 611. https:// of the earliest described cases included cases of hereditary spastic paraplegia, amyotrophic doi.org/10.3390/brainsci11050611 lateral sclerosis, and underrecognized structural, infectious, or inflammatory etiologies for upper motor neuron dysfunction which have since become routinely diagnosed with the Academic Editors: P.
    [Show full text]
  • AMYOTROPHIC LATERAL SCLEROSIS Spin21 (1)
    AMYOTROPHIC LATERAL SCLEROSIS Spin21 (1) Amyotrophic Lateral Sclerosis (ALS) Synonyms: CHARCOT'S DISEASE (in Europe), LOU GEHRIG'S DISEASE (in USA) Last updated: April 22, 2019 ETIOPATHOPHYSIOLOGY, PATHOLOGY .................................................................................................. 1 GENETICS ............................................................................................................................................... 3 EPIDEMIOLOGY ........................................................................................................................................ 3 Genetics ............................................................................................................................................ 3 CLINICAL FEATURES ............................................................................................................................... 3 EL ESCORIAL WORLD FEDERATION OF NEUROLOGY CRITERIA .............................................................. 4 CLINICAL COURSE & PROGNOSIS ........................................................................................................... 4 VARIANTS .............................................................................................................................................. 5 DIAGNOSIS................................................................................................................................................ 5 TREATMENT ............................................................................................................................................
    [Show full text]
  • Neural Control of Movement: Motor Neuron Subtypes, Proprioception and Recurrent Inhibition
    List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I Enjin A, Rabe N, Nakanishi ST, Vallstedt A, Gezelius H, Mem- ic F, Lind M, Hjalt T, Tourtellotte WG, Bruder C, Eichele G, Whelan PJ, Kullander K (2010) Identification of novel spinal cholinergic genetic subtypes disclose Chodl and Pitx2 as mark- ers for fast motor neurons and partition cells. J Comp Neurol 518:2284-2304. II Wootz H, Enjin A, Wallen-Mackenzie Å, Lindholm D, Kul- lander K (2010) Reduced VGLUT2 expression increases motor neuron viability in Sod1G93A mice. Neurobiol Dis 37:58-66 III Enjin A, Leao KE, Mikulovic S, Le Merre P, Tourtellotte WG, Kullander K. 5-ht1d marks gamma motor neurons and regulates development of sensorimotor connections Manuscript IV Enjin A, Leao KE, Eriksson A, Larhammar M, Gezelius H, Lamotte d’Incamps B, Nagaraja C, Kullander K. Development of spinal motor circuits in the absence of VIAAT-mediated Renshaw cell signaling Manuscript Reprints were made with permission from the respective publishers. Cover illustration Carousel by Sasha Svensson Contents Introduction.....................................................................................................9 Background...................................................................................................11 Neural control of movement.....................................................................11 The motor neuron.....................................................................................12 Organization
    [Show full text]
  • ALS and Other Motor Neuron Diseases Can Represent Diagnostic Challenges
    Review Article Address correspondence to Dr Ezgi Tiryaki, Hennepin ALS and Other Motor County Medical Center, Department of Neurology, 701 Park Avenue P5-200, Neuron Diseases Minneapolis, MN 55415, [email protected]. Ezgi Tiryaki, MD; Holli A. Horak, MD, FAAN Relationship Disclosure: Dr Tiryaki’s institution receives support from The ALS Association. Dr Horak’s ABSTRACT institution receives a grant from the Centers for Disease Purpose of Review: This review describes the most common motor neuron disease, Control and Prevention. ALS. It discusses the diagnosis and evaluation of ALS and the current understanding of its Unlabeled Use of pathophysiology, including new genetic underpinnings of the disease. This article also Products/Investigational covers other motor neuron diseases, reviews how to distinguish them from ALS, and Use Disclosure: Drs Tiryaki and Horak discuss discusses their pathophysiology. the unlabeled use of various Recent Findings: In this article, the spectrum of cognitive involvement in ALS, new concepts drugs for the symptomatic about protein synthesis pathology in the etiology of ALS, and new genetic associations will be management of ALS. * 2014, American Academy covered. This concept has changed over the past 3 to 4 years with the discovery of new of Neurology. genes and genetic processes that may trigger the disease. As of 2014, two-thirds of familial ALS and 10% of sporadic ALS can be explained by genetics. TAR DNA binding protein 43 kDa (TDP-43), for instance, has been shown to cause frontotemporal dementia as well as some cases of familial ALS, and is associated with frontotemporal dysfunction in ALS. Summary: The anterior horn cells control all voluntary movement: motor activity, res- piratory, speech, and swallowing functions are dependent upon signals from the anterior horn cells.
    [Show full text]
  • Approach to a Patient with Hemiplegia and Monoplegia
    CHAPTER Approach to a Patient with Hemiplegia and Monoplegia 27 Sudhir Kumar, Subhash Kaul INTRODUCTION 4. Injury to multiple cervical nerve roots. Monoplegia and hemiplegia are common neurological 5. Functional or psychogenic. symptoms in patients presenting to the emergency department as well as outpatient department. Insidious onset, gradually progressive monoplegia affecting lower limb can be caused by the following Monoplegia refers to weakness of one limb (either arm or conditions: leg) and hemiplegia refers to weakness of one arm and leg on the same side of body (either left or right side). 1. Tumor of the contralateral frontal lobe. There are a variety of underlying causes for monoplegia 2. Tumor of spinal cord at thoracic or lumbar level. and hemiplegia. The causes differ in different age groups. 3. Chronic infection of brain (frontal lobe) or spinal The causes also differ depending on the onset, progression cord (thoracic or lumbar level), such as tuberculous. and duration of weakness. Therefore, one needs to adopt a systematic approach during history taking and 4. Lumbosacral-plexopathy, due to diabetes mellitus. examination in order to arrive at the correct diagnosis. Insidious onset, gradually progressive monoplegia, Appropriate investigations after these would confirm the affecting upper limb, can be caused by one of the following diagnosis. conditions: The aim of this chapter is to systematically look at the 1. Tumor of the contralateral parietal lobe. differential diagnosis of monoplegia and hemiplegia and outline the approach needed to pinpoint the exact 2. Compressive lesion (tumor, large disc, etc) in underlying cause. cervical cord region. 3. Chronic infection of the brain (parietal lobe) or APPROACH TO THE DIAGNOSIS OF MONOPLEGIA spinal cord (cervical region), such as tuberculous.
    [Show full text]
  • Neuromuscular Disorders Neurology in Practice: Series Editors: Robert A
    Neuromuscular Disorders neurology in practice: series editors: robert a. gross, department of neurology, university of rochester medical center, rochester, ny, usa jonathan w. mink, department of neurology, university of rochester medical center,rochester, ny, usa Neuromuscular Disorders edited by Rabi N. Tawil, MD Professor of Neurology University of Rochester Medical Center Rochester, NY, USA Shannon Venance, MD, PhD, FRCPCP Associate Professor of Neurology The University of Western Ontario London, Ontario, Canada A John Wiley & Sons, Ltd., Publication This edition fi rst published 2011, ® 2011 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Palliative Care in Amyotrophic Lateral Sclerosis: from Diagnosis to Bereavement, 2Nd Edn, Pp
    Palliative Care in Amyotrophic Lateral Sclerosis From Diagnosis to Bereavement THIRD EDITION Edited by David Oliver Consultant in Palliative Medicine Wisdom Hospice, Rochester and Honorary Reader University of Kent, UK Gian Domenico Borasio Chair in Palliative Medicine Director, Palliative Care Service Centre Hospitalier Universitaire Vaudois University of Lausanne, Switzerland Wendy Johnston Professor of Neurology Director, ALS Programme University of Alberta, Canada 1 1 Great Clarendon Street, Oxford, OX2 6DP, United Kingdom Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries © Oxford University Press 2014 The moral rights of the authors have been asserted Second Edition published in 2006 9780199212934 HB 9780198570486 PB First Edition published in 2000 9780192631664 Impression: 1 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer Published in the United States of America by Oxford University Press 198 Madison Avenue, New York, NY 10016, United States of America British Library Cataloguing in Publication Data Data available Library of Congress Control Number: 2013950545 ISBN 978–0–19–968602–5 Printed and bound by CPI Group (UK) Ltd, Croydon, CR0 4YY Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct.
    [Show full text]
  • Motor Neuron Disease and the Elderly
    Neurology 61 Motor neuron disease and the elderly Motor neuron disease is a devastating condition characterised by degeneration of motor nerves. Many of the presenting symptoms, such as fatigue, muscle weakness and difficulty in swallowing have a broad differential diagnoses in the elderly population. Dr Sheba Azam and Professor PN Leigh explain how ensuring quality of life for patients requires preventing unnecessary delay in diagnosis and early referral to an appropriate multidisciplinary team. myotrophic lateral sclerosis (ALS) also cognitive changes. Thus, misdiagnosis as well as known as motor neuron disease (MND) under-investigation has been suggested as possible (the terms are used interchangeably), was causes of an apparent decrease in the incidence of A 4 fi rst described in 1869 by the French neurologist MND in later life . Jean-Martin Charcot1. It is a progressive, fatal neurological disease characterised by degeneration of motor nerve cells in the motor cortex, Prognostic factors corticospinal tract and the spinal cord anterior horn Although the average survival in MND is around cells. The degeneration of motor nerve cells results 36 months, some patients live for 10 years or more. in progressive muscle wasting leading to signifi cant Certain phenotypic variants appear to determine disability and ultimately death. Death usually survival rates. Using information held in a tertiary results from respiratory failure due to weakness of referral MND database, a group of researchers the respiratory muscles. analysed data on onset of disease, site of onset and duration of survival5. The authors concluded that typical MND with bulbar onset, onset later in life Incidence and prevalence or in the defi nite category of El Escorial (where The worldwide incidence of MND is approximately the World Federation of Neurologist meet to a professor of clinical two per 100,000 and the prevalence is four to seven decide diagnostic criteria) at presentation, per 100,000.
    [Show full text]
  • Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis
    1340 • The Journal of Neuroscience, February 11, 2004 • 24(6):1340–1349 Neurobiology of Disease Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis Minh Dang Nguyen,1 Thierry D’Aigle,2 Genevie`ve Gowing,1,2 Jean-Pierre Julien,1,2 and Serge Rivest2 1McGill University Health Center, Centre for Research in Neurosciences, McGill University, The Montreal General Hospital Research Institute, Montre´al, Que´bec H3G 1A4, Canada, and 2Laboratory of Molecular Endocrinology, Laval University Medical Center Research Center and Department of Anatomy and Physiology, Laval University, Sainte-Foy, Que´bec G1V 4G2, Canada Innate immunity is a specific and organized immunological program engaged by peripheral organs and the CNS to maintain homeostasis after stress and injury. In neurodegenerative disorders, its putative deregulation, featured by inflammation and activation of glial cells resulting from inherited mutations or viral/bacterial infections, likely contributes to neuronal death. However, it remains unclear to what extent environmental factors and innate immunity cooperate to modulate the interactions between the neuronal and non-neuronal elements in the perturbed CNS. In the present study, we addressed the effects of acute and chronic administration of lipopolysaccharide (LPS), a Gram-negative bacterial wall component, in a genetic model of neurodegeneration. Transgenic mice expressing a mutant form of the superoxide dismutase 1 (SOD1 G37R) linked to familial amyotrophic lateral sclerosis were challenged intraperitoneally with a single nontoxic or repeated injections of LPS (1 mg/kg). At different ages, SOD1 G37R mice responded normally to acute endotoxemia. Remark- ably, only a chronic challenge with LPS in presymptomatic 6-month-old SOD1 G37R mice exacerbated disease progression by 3 weeks and motor axon degeneration.
    [Show full text]
  • Lancl1 Promotes Motor Neuron Survival and Extends the Lifespan of Amyotrophic Lateral Sclerosis Mice
    Cell Death & Differentiation (2020) 27:1369–1382 https://doi.org/10.1038/s41418-019-0422-6 ARTICLE LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice 1 1 1 1 1 1 1 Honglin Tan ● Mina Chen ● Dejiang Pang ● Xiaoqiang Xia ● Chongyangzi Du ● Wanchun Yang ● Yiyuan Cui ● 1,2 1 1,3 4 4 3 1,5 Chao Huang ● Wanxiang Jiang ● Dandan Bi ● Chunyu Li ● Huifang Shang ● Paul F. Worley ● Bo Xiao Received: 19 November 2018 / Revised: 3 September 2019 / Accepted: 6 September 2019 / Published online: 30 September 2019 © The Author(s) 2019. This article is published with open access Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of motor neurons. Improving neuronal survival in ALS remains a significant challenge. Previously, we identified Lanthionine synthetase C-like protein 1 (LanCL1) as a neuronal antioxidant defense gene, the genetic deletion of which causes apoptotic neurodegeneration in the brain. Here, we report in vivo data using the transgenic SOD1G93A mouse model of ALS indicating that CNS-specific expression of LanCL1 transgene extends lifespan, delays disease onset, decelerates symptomatic progression, and improves motor performance of SOD1G93A mice. Conversely, CNS-specific deletion of fl 1234567890();,: 1234567890();,: LanCL1 leads to neurodegenerative phenotypes, including motor neuron loss, neuroin ammation, and oxidative damage. Analysis reveals that LanCL1 is a positive regulator of AKT activity, and LanCL1 overexpression restores the impaired AKT activity in ALS model mice. These findings indicate that LanCL1 regulates neuronal survival through an alternative mechanism, and suggest a new therapeutic target in ALS.
    [Show full text]
  • Motor Neurone Disease
    Neurology Motor neurone disease Margaret Zoing Matthew Kiernan Caring for the patient in general practice Motor neurone disease (MND) is a progressive Background neurodegenerative disease. It is characterised by motor Motor neurone disease is a neurodegenerative disease that systems failure that results in the death of nerves responsible leads to progressive disability – and eventually death – for all voluntary movements, leading to limb paralysis, within 2–3 years. weakness of the muscles of speech and swallowing, and Objective ultimately respiratory failure. Typically MND strikes patients This article describes the role of the general practitioner in at the prime of adult life, usually in the fifth to sixth decades, caring for patients with motor neurone disease. and has a short trajectory from diagnosis with an average life Discussion expectancy of less than 3 years.1 Current estimates are that The diagnosis of motor neurone disease relies on the 1400 people are living with MND in Australia at any time, presence of upper and lower motor neurone features. There with 370 newly diagnosed patients each year.2 More than one is currently no pathognomic test for motor neurone disease Australian dies every day from this most pernicious disease. and it largely remains a diagnosis of exclusion following an accurate clinical history, combined with basic screening The cause of MND remains unknown but appears heterogeneous. blood investigations and structural imaging of the brain Environmental factors may trigger an underlying susceptibility – toxins, and spinal cord. Neuro-physiological studies may be useful chemicals, metals and trauma have all been proposed.1 Most cases as an ancillary diagnostic tool.
    [Show full text]